Meanwhile, ANXA8 expression has been noted as significantly more enhanced in ovarian malignant tissues than benign tumours and normal ovarian tissues and is associated with a poor prognosis (Gou et al., 2019), and ANXA10 has recently been shown to be a prognostic biomarker for papillary thyroid cancer as well as a potential therapeutic target (Liu et al., 2021b). This evidence concerns the gene ANXA10 and thyroid gland papillary carcinoma.